CelLBxHealth guides for 50% revenue growth as partnership pipeline swells
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter. The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during 2025 and recruited new leadership to drive a partnership-focused strategy centred on pharmaceutical and diagnostic companies rather than research income.
Union Jack Oil 's Crossroads well disappoints with non-commercial result
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) said its Crossroads well in Garvin County, Oklahoma, has been deemed non-commercial following testing, marking a setback for the AIM-listed company's US drilling interests. The company, which holds a 43% interest in the well, said Crossroads encountered hydrocarbon shows at several levels from the Hoxbar down to the Basal McLish intervals.
Bet on 5 Top-Ranked Stocks With Rising P/E for Solid Returns
Rising P/E ratios can signal confidence and momentum. Discover 5 stocks backed by strong earnings growth and upside potential.
Optima Health trading 'in line' as it continues to grow UK and Ireland platform
Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N) said full-year revenue rose around 15% to approximately £121 million for the year ended 31 March 2026, in line with market expectations, as the occupational health and wellbeing services provider continued to grow its UK and Ireland platform. The AIM-listed group said adjusted EBITDA for FY26 is expected to be around 10% ahead of previous market expectations, as previously announced.
Union Jack Oil reveals takeover approach by Reabold Resources
Union Jack Oil PLC (AIM:UJO, OTCQB:UJOGF, FRA:1UJ0) announced it has received a non-binding approach from Reabold Resources PLC (AIM:RBD, FRA:AWL1) over a possible all-share takeover. The AIM-listed oil and gas company said Reabold sent an indicative offer letter on 1 June 2026 covering a possible offer for Union Jack's entire issued share capital.
Poolbeg Pharma shows clinical progress with latest updates
Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company said the trial is assessing POLB 001 as a potential preventative for cytokine release syndrome, or CRS, in around 30 relapsed/refractory multiple myeloma patients receiving the approved bispecific antibody teclistamab.
PAF raises £800,000 to advance Zimbabwe lithium project
Premier African Minerals Ltd (AIM:PREM, OTC:PRMMF) shares oscillated between a 4% rise and a 14% loss after the company raised £800,000 to support ongoing work at its Zulu lithium and tantalum project in Zimbabwe. The AIM-listed miner said it had completed a subscription for 4 billion new shares at 0.02p each, with the proceeds earmarked for operational activities at Zulu and general working capital.
Coastal Africa joins AIM with BP topping up £27m coffers
Coastal Africa Group Ltd (AIM:CAGL) arrived to a warm AIM welcome on Wednesday with £27 million of fresh capital, backing from BP PLC (LSE:BP.) and a promise to hunt for oil and gas assets across West Africa.
Coiled Therapeutics strengthens its scientific bench
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF) has strengthened the scientific bench behind its lead cancer drug candidate AO-252, appointing Professor Ozgur Sahin as scientific advisor as the programme approaches a series of clinical milestones. The AIM-listed oncology company said Sahin, a named inventor on foundational patents underpinning AO-252, is one of the world's leading authorities on TACC3 biology.
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcript
The Hour-Long Project We Never Would've Started
By Andrew Rice, Partner and Portfolio Manager We may often come off as skeptical about AI in our newsletter. Our skepticism is primarily centered on the AI capital spend and AI company valuations rather than the AI tools themselves, which we have found both useful and exciting.
Creo Medical Group to raise £5.5m and advance partial divestment
Creo Medical Group PLC (AIM:CREO, FRA:1RC, OTC:CMEOF) announced plans to raise approximately £5.5 million through a placing as the medical device company moves to strengthen its balance sheet while pursuing the sale of its remaining stake in Creo Medical Europe. The AIM-listed group said it intends to issue around 36.7 million new shares at 15p each, a 31.9% premium to Thursday's closing mid-market price of 11.4p.
